The American College of Rheumatology (ACR) most recently published recommendations for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA) in 2008. These recommendations covered indications for use, monitoring of side effects, assessment of the clinical response to DMARDs and biologic agents, screening for tuberculosis (TB), and assessment of the roles of cost patient preference in decision making for biologic agents. Recognizing the rapidly evolving knowledge in RA management and the accumulation of new evidence regarding the safety and efficacy of existing and newer ther and thertherapies, the ACR commissioned an update of the 2008 recommendations in select topic areas.
The 2012 revision updates the 2008 ACR recommendations in the following areas: 1) indications for DMARDs and biologic agents, 2) switching between DMARD and biologic therapies, 3) use of biologic agents in high-risk patients (those with hepatitis, congestive heart failure [CHF], and malignancy), 4) screening for TB in patients starting or currently receiving biologic agents, and 5) vaccination in patients starting or currently receiving DMARDs or biologic agents.
版权声明
本网站所有注明“来源：丁香园”的文字、图片和音视频资料，版权均属于丁香园所有，非经授权，任何媒体、网站或个人不得转载，授权转载时须注明“来源：丁香园”。本网所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。同时转载内容不代表本站立场。
风湿免疫病相关文章
